Business
Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control
--Advances European commercialization strategy following CE mark approval-- ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced that it received the Medicines and Healthcare products Regulatory Agency (MHRA) approval for its FemBloc Permanent Birth Control, which signifies the product has met the required standards for safet
About this update from Femasys Inc.
[{"type":"image","alt":"Femasys Inc.","displaySize":"","headline":null,"caption":"Femasys Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GL8WCCgrHOHP9r8Vdi7XpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825","width":300,"height":122}},"lazy":false},{"type":"text","content":"--Advances European commercialization strategy following CE mark approval--","length":75,"tagName":"p"},{"type":"text","content":"ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced that it received the Medicines and Healthcare products Regulatory Agency (MHRA) approval for its FemBloc Permanent Birth Control, which signifies the product has met the required standards for safety, quality, and effectiveness in the United Kingdom (UK). This marks an important milestone in the Company’s efforts to expand availability of this revolutionary non-surgical permanent birth control option to women in Europe.","length":649,"tagName":"p"},{"type":"text","content":"“The UK’s regulatory approval for FemBloc permanent birth control is another milestone in our global expansion strategy,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “This follows our recent CE mark for Europe and reinforces our momentum toward broader international market access. This achievement demonstrates regulatory confidence in our technology and positions us to move forward with securing a strategic partner to support commercialization in the UK.”","length":491,"tagName":"p"},{"type":"text","content":"The United Kingdom represents one of the largest and most influential healthcare markets in Europe, with a strong emphasis on advancing women’s health solutions. With the UK’s single-payer National Health Service (NHS), innovative technologies that improve access, reduce costs, and enhance outcomes have a clear pathway to broad adoption. Securing MHRA approval not only validates FemBloc’s safety and effectiveness but also enables Femasys to serve a diverse patient pop...